Oncology Brothers: Practice-Changing Cancer Discussions cover image

How to Treat Diffuse Large B-Cell Lymphoma (DLBCL) in 2025

Oncology Brothers: Practice-Changing Cancer Discussions

00:00

Relapse Options: Bispecifics, Sequencing, and Toxicities

Discussion of bispecific antibodies (practical community distinctions), sequencing after CAR‑T failure (pola‑BR, tafasitamab, combos), and long‑term immunosuppression, CRS/ICANS awareness, and infection prophylaxis.

Play episode from 16:22
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app